ASH 2023 | Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, reports favorable long-term outcomes for patients with IGHV-mutated chronic lymphocytic leukemia (CLL) treated with ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) in a Phase II trial (NCT02629809). This trial yielded a high rate of undetectable measurable residual disease (MRD) in bone marrow and a six-year progression-free survival (PFS) upwards of 92%. Despite these promising results, the CLL landscape is shifting away from chemotherapy, potentially limiting the clinical adoption of this regimen. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Honoraria: AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Other (Travel, Accommodation, Expenses): AbbVie, Cellectis, TG Therapeutics, Genentech, Beigene, CareDX, Ipsen, MEI Pharma, Janssen, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
Research Funding: AbbVie, Cellectis, Takeda, Genentech, ADC Therapeutics, Servier, TransThera Sciences, Mingsight, Aprea Therapeutics, Medisix, Incyte, Newave, Fate Therapeutics, Dialectic Therapeutics, Novalgen, Loxo Oncology, Pfizer, Precision Biosciences, Pharmacyclics, AstraZeneca, Kite/Gilead, Adaptive Biotechnologies, BMS
